T cell repertoire following autologous stem cell transplantation for multiple sclerosis

Journal of Clinical Investigation

Volumn 124, Issue 3, 2014, Pages 1168-1172

  Muraro, Paolo A ^a   Robins, Harlan ^b   Malhotra, Sachin ^c   Howell, Michael ^c   Phippard, Deborah ^c   Desmarais, Cindy ^d   De Paula Alves Sousa, Alessandra ^a   Griffith, Linda M ^e   Lim, Noha ^c   Nash, Richard A ^f   Turka, Laurence A ^c,g  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b Fred Hutchinson Cancer Research Center   (United States)

^c Immune Tolerance Network   (United States)

^d ADAPTIVE BIOTECHNOLOGIES   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f Rocky Mountain Blood and Marrow Transplant Program   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CD4 ANTIGEN; CD8 ANTIGEN; CYTARABINE; ETOPOSIDE; MELPHALAN; T LYMPHOCYTE RECEPTOR BETA CHAIN; THYMOCYTE ANTIBODY;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HIGH THROUGHPUT SEQUENCING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MOLECULAR CLONING; MULTICENTER STUDY; MULTIPLE SCLEROSIS; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; T LYMPHOCYTE; TREATMENT RESPONSE;

CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CLINICAL TRIALS, PHASE II AS TOPIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IMMUNOSUPPRESSION; MULTICENTER STUDIES AS TOPIC; MULTIPLE SCLEROSIS; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84896775850     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI71691     Document Type: Article

References (15)

1. Sykes M, Nikolic B. Treatment of severe autoimmune disease by stem-cell transplantation. Nature. 2005;435(7042):620-627.
2. Muraro PA, et al. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med. 2005;201(5):805-816.
3. de Kleer I, et al. Autologous stem cell transplantation for autoimmunity induces immunologic selftolerance by reprogramming autoreactive T cells and restoring the CD4+CD25+ immune regulatory network. Blood. 2006;107(4):1696-1702.
4. Muraro PA, Douek DC. Renewing the T cell repertoire to arrest autoimmune aggression. Trends Immunol. 2006;27(2):61-67.
5. Dubinsky AN, Burt RK, Martin R, Muraro PA. T-cell clones persisting in the circulation after autologous hematopoietic SCT are undetectable in the peripheral CD34+ selected graft. Bone Marrow Transplant. 2010;45(2):325-331.
6. Mamedov IZ, et al. Quantitative tracking of T cell clones after haematopoietic stem cell transplantation. EMBO Mol Med. 2011;3(4):201-207.
7. Robins HS, et al. Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. Blood. 2009;114(19):4099-4107.
8. Bosch M, Khan FM, Storek J. Immune reconstitution after hematopoietic cell transplantation. Curr Opin Hematol. 2012;19(4):324-335.
9. Efron B, Thisted R. Estimating the number of unseen species: how many words did Shakespeare know? Biometrika. 1976;63(3):435-447.
10. Fisher RA, Corbet AS, Williams CB. The relation between the number of species and the number of individuals in a random sample of an animal population. J Anim Ecol. 1943;12(1):42-58.
11. van Heijst JW, et al. Quantitative assessment of T cell repertoire recovery after hematopoietic stem cell transplantation. Nat Med. 2013; 19(3):372-377.
12. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med. 2007;357(25):2601-2614.
13. Miles JJ, Douek DC, Price DA. Bias in the alphabeta T-cell repertoire: implications for disease pathogenesis and vaccination. Immunol Cell Biol. 2011; 89(3):375-387.
14. Klarenbeek PL, et al. Deep sequencing of antiviral T-cell responses to HCMV and EBV in humans reveals a stable repertoire that is maintained for many years. PLoS Pathog. 2012;8(9):e1002889.
15. Nash RA, et al. Treatment of severe relapsingremitting multiple sclerosis with high-dose immunosuppressive therapy and autologous hematopoietic cell transplantation: 2-year follow-up results of the HALT MS Clinical Trial (Immune Tolerance Network: ITN033AI). Biol Blood Marrow Transplant. 2013;19(2 suppl):S129.